Summer Sale! Save 25%
- NAMENDA is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.
- Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation.
• Drugs that Make the Urine Alkaline
The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.
• Use with Other N-methyl-D-aspartate (NMDA) Antagonists
The combined use of NAMENDA with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.
• Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine.
